MacroGenics, Inc. (NASDAQ:MGNX) SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at $700,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jon Marc Wigginton also recently made the following trade(s):

  • On Wednesday, October 25th, Jon Marc Wigginton sold 10,000 shares of MacroGenics stock. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00.

MacroGenics, Inc. (MGNX) traded up $0.33 during mid-day trading on Wednesday, reaching $20.03. 213,800 shares of the company’s stock were exchanged, compared to its average volume of 261,368. MacroGenics, Inc. has a 1 year low of $14.36 and a 1 year high of $28.90.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $5.50 million. During the same period last year, the firm earned ($0.97) earnings per share. The company’s revenue for the quarter was down 48.5% compared to the same quarter last year. equities analysts predict that MacroGenics, Inc. will post -0.7 EPS for the current year.

WARNING: “MacroGenics, Inc. (MGNX) SVP Jon Marc Wigginton Sells 5,000 Shares” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/macrogenics-inc-mgnx-svp-jon-marc-wigginton-sells-5000-shares/1720228.html.

Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. bought a new position in MacroGenics during the second quarter worth $133,000. Legal & General Group Plc boosted its position in MacroGenics by 4.3% during the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 328 shares during the period. SG Americas Securities LLC boosted its position in MacroGenics by 92.2% during the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 5,187 shares during the period. Parametric Portfolio Associates LLC bought a new position in MacroGenics during the second quarter worth $203,000. Finally, Virtu KCG Holdings LLC bought a new position in MacroGenics during the second quarter worth $232,000. 82.75% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on MGNX shares. Stifel Nicolaus reissued a “buy” rating and issued a $34.00 target price on shares of MacroGenics in a research note on Tuesday, September 12th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $26.00 target price on shares of MacroGenics in a research note on Friday, September 1st. Finally, ValuEngine raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $30.10.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.